We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$124M
Cap. Flow
-$115M
Cap. Flow %
-22.13%
Top 10 Hldgs %
61.71%
Holding
72
New
27
Increased
15
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$12.5M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$11.2M
3
VTRS icon
Viatris
VTRS
+$9.9M
4
ARQL
Arqule Inc
ARQL
+$9.88M
5
TXMD icon
TherapeuticsMD
TXMD
+$8.01M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$19.3M
2
PCRX icon
Pacira BioSciences
PCRX
+$18.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$16.5M
4
CLLS
Cellectis
CLLS
+$15.5M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$95.9M 18.37%
1,000,000
-1,000,000
-50% -$97M
EXEL icon
2
Exelixis
EXEL
$14B
$30.7M 5.89%
1,735,030
+313,430
+22% +$6.11M
AGN
3
DELISTED
Allergan plc
AGN
$30.2M 5.79%
158,712
-63,401
-29% -$11.6M
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$29.1M 5.58%
1,398,577
+69,473
+5% +$1.65M
BMRN icon
5
CALL
BioMarin Pharmaceuticals
BMRN
$11.3B
$29.1M 5.57%
300,000
– –
VTRS icon
6
Viatris
VTRS
$19.8B
$25.5M 4.88%
695,788
+263,779
+61% +$9.9M
DOVA
7
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$21.5M 4.13%
1,026,906
+206,558
+25% +$4.92M
BOLD
8
DELISTED
Audentes Therapeutics, Inc
BOLD
$21.4M 4.11%
541,172
+299,672
+124% +$11.2M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$20.9M 4%
549,231
+145,139
+36% +$6.43M
TVRD
10
Tvardi Therapeutics
TVRD
$24.2M
$17.7M 3.38%
20,481
+8,375
+69% +$6.05M
BHC icon
11
Bausch Health
BHC
$1.68B
$14M 2.68%
+545,500
New +$12.5M
ECYT
12
DELISTED
Endocyte, Inc. Common Stock
ECYT
$11.6M 2.23%
654,532
+58,532
+10% +$1M
ABEO icon
13
Abeona Therapeutics
ABEO
$364M
$10.9M 2.09%
33,999
+8,927
+36% +$3.17M
ACAD icon
14
CALL
Acadia Pharmaceuticals
ACAD
$4.27B
$10.4M 1.99%
+500,000
New +$7.87M
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$10.1M 1.93%
908,664
+80,009
+10% +$994K
ARQL
16
DELISTED
Arqule Inc
ARQL
$9.83M 1.88%
+1,737,397
New +$9.88M
STML
17
DELISTED
Stemline Therapeutics, Inc.
STML
$9.66M 1.85%
582,070
+22,553
+4% +$362K
GYRE icon
18
Gyre Therapeutics
GYRE
$663M
$9.62M 1.84%
119,011
+14,096
+13% +$1.12M
INSM icon
19
Insmed
INSM
$23.3B
$9.38M 1.8%
464,159
-182,704
-28% -$4.13M
TXMD icon
20
TherapeuticsMD
TXMD
$24M
$8.57M 1.64%
+26,142
New +$8.01M
NKTR icon
21
Nektar Therapeutics
NKTR
$2.32B
$7.8M 1.5%
+8,533
New +$7.28M
AZN icon
22
AstraZeneca
AZN
$261B
$7.65M 1.47%
96,640
-163,500
-63% -$12.4M
ACHN
23
DELISTED
Achillion Pharmaceuticals
ACHN
$5.83M 1.12%
+1,583,954
New +$4.72M
VKTX icon
24
Viking Therapeutics
VKTX
$4.19B
$5.71M 1.09%
+327,730
New +$3.9M
KURA icon
25
Kura Oncology
KURA
$929M
$5.45M 1.04%
311,536
-69,923
-18% -$1.34M
1
2 3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Nexthera Capital held 72 positions worth $522M, down 19% from $646M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Nexthera Capital withdrew a net $115M in Q3 2018, closing 16 positions and reducing 12 holdings. Its most notable exit was TESARO, Inc., an estimated $19.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 60% a quarter earlier.

Against the trend, Nexthera Capital opened a new position in Bausch Health worth $14M.

  • Nexthera Capital's largest Q3 2018 buy was Bausch Health: 545,500 shares worth $14M.
  • Nexthera Capital added most to Audentes Therapeutics, Inc in Q3 2018, an estimated $11.2M increase.
  • Nexthera Capital's biggest Q3 2018 reduction was AstraZeneca, cutting an estimated $12.4M.
  • Nexthera Capital fully exited TESARO, Inc. in Q3 2018, selling an estimated $19.3M.
  • Nexthera Capital's ten largest holdings make up 62% of its $522M portfolio in Q3 2018.
  • Nexthera Capital opened 27 new positions and closed 16 in Q3 2018.
  • Nexthera Capital's portfolio value fell 19% quarter-over-quarter to $522M.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.